Company news
Nuwellis, Inc. news in 2022
Nuwellis, Inc.'s news releases, calls and decks from 2022, newest first.
Nuwellis, Inc. Announces Compliance With Nasdaq Listing Requirements
December 26, 2022
Nuwellis Announces Data Supporting Lower Heart Failure Hospitalizations and Readmissions With Aquadex
December 12, 2022
Nuwellis, Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
December 7, 2022
Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
November 29, 2022
Nuwellis, Inc. Reports Third Quarter 2022 Financial Results
November 7, 2022
Nuwellis Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using a Modified Aquadex in Low-Birth-Weight Preterm Neonates
November 2, 2022
Nuwellis, Inc. To Announce Third Quarter 2022 Financial Results on November 8, 2022
October 18, 2022
Nuwellis Announces Appointment of Chief Financial Officer
October 18, 2022
Nuwellis Announces Closing of $11.04 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
October 17, 2022
Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering
October 13, 2022
Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting
October 2, 2022
Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial
September 26, 2022
Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients
August 30, 2022
Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 18, 2022
Nuwellis, Inc. Announces Second Quarter 2022 Financial Results
August 8, 2022
Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA
July 25, 2022
Nuwellis, Inc. To Announce Second Quarter 2022 Financial Results on August 9, 2022
July 13, 2022
Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy
July 11, 2022
Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF
June 28, 2022
Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas
June 13, 2022
Nuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum
May 16, 2022
Nuwellis, Inc. Announces First Quarter 2022 Financial Results
May 9, 2022
Nuwellis Announces Presentation of Aquadex®-Related Abstracts at the 2022 Pediatric Academic Societies Meeting
May 8, 2022
Nuwellis, Inc. To Announce First Quarter 2022 Financial Results on May 10, 2022
April 11, 2022
Nuwellis Announces IRB Approval to Begin Its REVERSE-HF Clinical Study
March 14, 2022
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022
Nuwellis Initiates REVERSE-HF Study to Evaluate Ultrafiltration for Heart Failure Patients with Fluid Overload
February 16, 2022
Nuwellis, Inc. to Announce Fourth Quarter 2021 Financial Results on March 1, 2022
January 31, 2022